Early-onset pathogens and foci following CAR T-cell therapy. (A) Early-onset infections and (B) infection foci after (i) anti-BCMA CAR T-cell therapy (n = 10), (ii) anti-CD19 CAR T-cell therapy (n = 42), and (iii) overall cohort receiving either CAR T-cell therapy (n = 52).